Lung Cancer
Volume 70, Issue 2 , Pages 174-179 , November 2010

Clinical outcomes in extracranial tumor sites and unusual toxicities with concurrent whole brain radiation (WBRT) and Erlotinib treatment in patients with non-small cell lung cancer (NSCLC) with brain metastasis

  • Inan Olmez

      Affiliations

    • Department of Pediatrics, Maimonides Medical Center, 4802 Tenth Avenue, Brooklyn, NY 11219, USA
    • ,
  • Bernadine R. Donahue

      Affiliations

    • Department of Radiation Oncology, Maimonides Medical Center, 6300 Eighth Avenue, Brooklyn, NY 11220, USA
    • ,
  • James S. Butler

      Affiliations

    • Department of Radiation Oncology, Maimonides Medical Center, 6300 Eighth Avenue, Brooklyn, NY 11220, USA
    • ,
  • Yiwu Huang

      Affiliations

    • Division of Hematology and Oncology, Department of Internal Medicine, Maimonides Medical Center, 6300 Eighth Avenue, Brooklyn, NY 11220, USA
    • ,
  • Philip Rubin

      Affiliations

    • Division of Hematology and Oncology, Department of Internal Medicine, Maimonides Medical Center, 6300 Eighth Avenue, Brooklyn, NY 11220, USA
    • ,
  • Yiqing Xu

      Affiliations

    • Division of Hematology and Oncology, Department of Internal Medicine, Maimonides Medical Center, 6300 Eighth Avenue, Brooklyn, NY 11220, USA
    • Corresponding Author InformationCorresponding author. Tel.: +1 718 765 2600; fax: +1 718 765 2630.

Received 14 September 2009 ,Revised 4 December 2009 ,Accepted 26 January 2010.

References 

  1. Posner JB. Management of brain metastases. Rev Neurol (Paris). 1992;148:477–487
  2. Shepherd FA, Rodrigues Pereira J, Ciuleanu T, Tan EH, Hirsh V, Thongprasert S, et al. Erlotinib in previously treated non-small-cell lung cancer. N Engl J Med. 2005;353:123–132
  3. Lynch TJ, Bell DW, Sordella R, Gurubhagavatula S, Okimoto RA, Brannigan BW, et al. Activating mutations in the epidermal growth factor receptor underlying responsiveness of non-small-cell lung cancer to gefitinib. N Engl J Med. 2004;350:2129–2139
  4. Tsao MS, Sakurada A, Cutz JC, Zhu CQ, Kamel-Reid S, Squire J, et al. Erlotinib in lung cancer—molecular and clinical predictors of outcome. N Engl J Med. 2005;353:133–144
  5. Zhu CQ, da Cunha Santos G, Ding K, Sakurada A, Cutz JC, Liu N, et al. Role of KRAS and EGFR as biomarkers of response to erlotinib in National Cancer Institute of Canada Clinical Trials Group Study BR.21. J Clin Oncol. 2008;26:4268–4275
  6. Gaspar L, Scott C, Rotman M, Asbell S, Phillips T, Wasserman T, et al. Recursive partitioning analysis (RPA) of prognostic factors in three Radiation Therapy Oncology Group (RTOG) brain metastases trials. Int J Radiat Oncol Biol Phys. 1997;37:745–751
  7. Therasse P, Arbuck SG, Eisenhauer EA, Wanders J, Kaplan RS, Rubinstein L, et al. New guidelines to evaluate the response to treatment in solid tumors. European Organization for Research and Treatment of Cancer, National Cancer Institute of the United States, National Cancer Institute of Canada. J Natl Cancer Inst. 2000;92:205–216
  8. Common toxicity criteria. Bethesda: National Institute of Health, Cancer Therapy Evaluation Program, Division of Cancer Treatment; 2006;
  9. Sasaki H, Endo K, Takada M, Kawahara M, Kitahara N, Tanaka H, et al. L858R EGFR mutation status correlated with clinico-pathological features of Japanese lung cancer. Lung Cancer. 2006;54:103–108
  10. Rosell R, Taron M, Sanchez JJ, Paz-Ares L. Setting the benchmark for tailoring treatment with EGFR tyrosine kinase inhibitors. Future Oncol. 2007;3:277–283
  11. Pao W, Miller V, Zakowski M, Doherty J, Politi K, Sarkaria I, et al. EGF receptor gene mutations are common in lung cancers from “never smokers” and are associated with sensitivity of tumors to gefitinib and erlotinib. Proc Natl Acad Sci USA. 2004;101:13306–13311
  12. Gow CH, Chien CR, Chang YL, Chiu YH, Kuo SH, Shih JY, et al. Radiotherapy in lung adenocarcinoma with brain metastases: effects of activating epidermal growth factor receptor mutations on clinical response. Clin Cancer Res. 2008;14:162–168
  13. Ma S, Xu Y, Deng Q, Yu X. Treatment of brain metastasis from non-small cell lung cancer with whole brain radiotherapy and Gefitinib in a Chinese population. Lung Cancer. 2008;
  14. Krishnan S, Brown PD, Ballman KV, Fiveash JB, Uhm JH, Giannini C, et al. Phase I trial of erlotinib with radiation therapy in patients with glioblastoma multiforme: results of North Central Cancer Treatment Group protocol N0177. Int J Radiat Oncol Biol Phys. 2006;65:1192–1199
  15. Brown PD, Krishnan S, Sarkaria JN, Wu W, Jaeckle KA, Uhm JH, et al. Phase I/II trial of erlotinib and temozolomide with radiation therapy in the treatment of newly diagnosed glioblastoma multiforme: North Central Cancer Treatment Group Study N0177. J Clin Oncol. 2008;26:5603–5609
  16. Lind JS, Lagerwaard FJ, Smit EF, Senan S. Phase I study of concurrent whole brain radiotherapy and erlotinib for multiple brain metastases from non-small-cell lung cancer. Int J Radiat Oncol Biol Phys. 2009;74:1391–1396
  17. Hidalgo M, Siu LL, Nemunaitis J, Rizzo J, Hammond LA, Takimoto C, et al. Phase I and pharmacologic study of OSI-774, an epidermal growth factor receptor tyrosine kinase inhibitor, in patients with advanced solid malignancies. J Clin Oncol. 2001;19:3267–3279
  18. Siegel-Lakhai WS, Beijnen JH, Schellens JH. Current knowledge and future directions of the selective epidermal growth factor receptor inhibitors erlotinib (Tarceva) and gefitinib (Iressa). Oncologist. 2005;10:579–589
  19. Nyati MK, Maheshwari D, Hanasoge S, Sreekumar A, Rynkiewicz SD, Chinnaiyan AM, et al. Radiosensitization by pan ErbB inhibitor CI-1033 in vitro and in vivo. Clin Cancer Res. 2004;10:691–700
  20. Chinnaiyan P, Huang S, Vallabhaneni G, Armstrong E, Varambally S, Tomlins SA, et al. Mechanisms of enhanced radiation response following epidermal growth factor receptor signaling inhibition by erlotinib (Tarceva). Cancer Res. 2005;65:3328–3335
  21. Andrews DW, Scott CB, Sperduto PW, Flanders AE, Gaspar LE, Schell MC, et al. Whole brain radiation therapy with or without stereotactic radiosurgery boost for patients with one to three brain metastases: phase III results of the RTOG 9508 randomised trial. Lancet. 2004;363:1665–1672
  22. Lang F, Wildrick DM, Sawaya R. Metastatic brain tumor. In:  Berger MS editors. Neuro-oncology: the essentials. Thieme Medical Publishers; 2000;p. 330
  23. Cohen MH, Williams GA, Sridhara R, Chen G, Pazdur R. FDA drug approval summary: gefitinib (ZD1839) (Iressa) tablets. Oncologist. 2003;8:303–306
  24. Takano T, Ohe Y, Kusumoto M, Tateishi U, Yamamoto S, Nokihara H, et al. Risk factors for interstitial lung disease and predictive factors for tumor response in patients with advanced non-small cell lung cancer treated with gefitinib. Lung Cancer. 2004;45:93–104
  25. Cohen MH, Johnson JR, Chen YF, Sridhara R, Pazdur R. FDA drug approval summary: erlotinib (Tarceva) tablets. Oncologist. 2005;10:461–466

PII: S0169-5002(10)00061-9

doi: 10.1016/j.lungcan.2010.01.018

Lung Cancer
Volume 70, Issue 2 , Pages 174-179 , November 2010

Article Tools